Litcius/Paper detail

Post-Transplantation Multicolored Flow Cytometry–Minimal Residual Disease Status on Day 100 Predicts Outcomes for Patients With Refractory Acute Myeloid Leukemia

Evgeny Klyuchnikov, Anita Badbaran, Radwan Massoud, Ulrike Fritsche-Friedland, Dietlinde Janson, Francis Ayuk, Maximilian Christopeit, Christine Wolschke, Ulrike Bacher, Nicolaus Kröger

2022Transplantation and Cellular Therapy11 citationsDOI

Topics & Concepts

MedicineInternal medicineTransplantationMyeloid leukemiaFludarabineMinimal residual diseaseUnivariate analysisRefractory (planetary science)CytarabineLeukemiaProportional hazards modelGastroenterologyOncologySurgeryMultivariate analysisChemotherapyAstrobiologyPhysicsCyclophosphamideAcute Myeloid Leukemia ResearchHematopoietic Stem Cell TransplantationAcute Lymphoblastic Leukemia research
Post-Transplantation Multicolored Flow Cytometry–Minimal Residual Disease Status on Day 100 Predicts Outcomes for Patients With Refractory Acute Myeloid Leukemia | Litcius